Asgard Therapeutics Raises €30M in Series A Financing
Summary
Asgard Therapeutics, a Lund, Sweden-based biotech company developing in vivo direct cell reprogramming for cancer immunotherapy, raised €30M in Series A funding. Led by CEO Cristiana Pires, Asgard Therapeutics is a preclinical stage biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. Commenting on the news, Cristiana Pires said: “Asgard’s technology overcomes challenges faced by traditional cell therapies, enabling the recreation of desired functional immune cells directly inside the patient’s body. We would like to thank both new and existing investors for their support as we discover and develop innovative immunotherapies with breakthrough potential and look forward to progressing our lead program AT-108 to the clinic.”